Previous 10 | Next 10 |
home / stock / idrsf / idrsf news
2023-10-24 09:30:11 ET More on Idorsia Idorsia's Insomniac Earnings And The Sell Signal That Won't Sleep Idorsia Ltd 2023 Q2 - Results - Earnings Call Presentation Idorsia Ltd (IDRSF) Q2 2023 Earnings Call Transcript Historical earnings data for Idorsia ...
2023-09-05 05:56:45 ET Summary Idorsia's Q2 2023 earnings and sales were below expectations, leading to concerns about the company's financial position. Sales growth for Idorsia's anti-insomnia drug, daridorexant, has been slow and disappointing, and no sign things will get better...
2023-07-29 12:53:06 ET Idorsia Ltd (IDRSF) Q2 2023 Earnings Conference Call July 25, 2023 09:00 AM ET Company Participants Andrew Weiss - Head of IR Jean-Paul Clozel - CEO Andre Muller - EVP & CFO Patricia Torr - VP, Head of US Finance & Infrastructur...
2023-07-26 05:51:17 ET Summary Idorsia announced a cost reduction target to reduce operating expenses by approximately 50%. Idorsia also sold its APAC (ex-China) license for CHF 400 million to extend its cash burn until 2024. We confirmed our Idorsia stock's neutral rating. Pr...
2023-07-25 09:43:33 ET Idorsia press release ( OTC:IDRSF ): 1H GAAP EPS of -CHF2.28. Revenue of CHF51M (+131.8% Y/Y). For further details see: Idorsia GAAP EPS of -CHF2.28, revenue of CHF51M
Allschwil, Switzerland – June 2 6 , 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as ...
2023-06-10 09:22:00 ET Summary Idorsia missed sales expectations by 47% and is urgently seeking funding to avoid equity issuance. We have cut our Quviviq sales expectations and pushed out the timeline to profitability to 2026. We downgrade Idorsia to neutral with a 12-month ta...
2023-04-30 23:57:33 ET Summary Downgrade to Sell: Due to lower-than-expected sales of Quviviq and clazosentan (Pivlaz), high cash burn, and a short cash runway, we are downgrading our rating on Idorsia stock to Sell. Disappointing Q1 2023 Results: Idorsia's Q1 performance fell sho...
2023-04-26 13:31:36 ET Idorsia press release ( OTC:IDRSF ): Q1 GAAP EPS of -CHF1.19. Revenue of CHF21M (+320.0% Y/Y). For further details see: Idorsia GAAP EPS of -CHF1.19, revenue of CHF21M
2023-04-26 11:35:44 ET Summary Idorsia missed top-line sales estimates. Only a quarter of liquidity, there was no funding news, and this increased the risk of equity dilution. Idorsia confirmed its 2025 financial targets but is lagging behind 2023 sales. Idorsia ( ...
News, Short Squeeze, Breakout and More Instantly...
Idorsia AG Company Name:
IDRSF Stock Symbol:
OTCMKTS Market:
Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod. Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone pay...
Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentati...
Allschwil, Switzerland – June 2 6 , 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as ...